Alterity Therapeutics Ltd (ASX: ATH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Alterity Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$92.44 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
10.88 billion
Earnings per share
-0.002
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Alterity Therapeutics Ltd (ASX: ATH)
Latest News
Healthcare Shares
Why the Alterity (ASX:ATH) share price is skyrocketing 42% today
Share Market News
Here's why the Alterity Therapeutics (ASX:ATH) share price blasted 20% higher today
Share Market News
Why Alterity Therapeutics (ASX:ATH) share price has surged up 27% today
Share Market News
Alterity (ASX:ATH) share price lower on completed placement
⏸️ Investing
Why Alterity Therapeutics' share price has rocketed 96% in 2 days
Share Market News
Alterity Therapeutics share price rockets 70% on new data
Share Market News
Why Etherstack and these shares were the most traded on the ASX last week
ATH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Alterity Therapeutics Ltd
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
ATH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Jan 2026 | $0.01 | $0.00 | 0.00% | 2,665,442 | $0.01 | $0.01 | $0.01 |
| 12 Jan 2026 | $0.01 | $0.00 | 0.00% | 391,993 | $0.01 | $0.01 | $0.01 |
| 09 Jan 2026 | $0.01 | $0.00 | 0.00% | 924,847 | $0.01 | $0.01 | $0.01 |
| 08 Jan 2026 | $0.01 | $0.00 | 0.00% | 232,136 | $0.01 | $0.01 | $0.01 |
| 07 Jan 2026 | $0.01 | $0.00 | 0.00% | 362,335 | $0.01 | $0.01 | $0.01 |
| 06 Jan 2026 | $0.01 | $0.00 | 0.00% | 540,142 | $0.01 | $0.01 | $0.01 |
| 05 Jan 2026 | $0.01 | $0.00 | 0.00% | 454,705 | $0.01 | $0.01 | $0.01 |
| 02 Jan 2026 | $0.01 | $0.00 | 0.00% | 883,780 | $0.01 | $0.01 | $0.01 |
| 31 Dec 2025 | $0.01 | $0.00 | 0.00% | 389,358 | $0.01 | $0.01 | $0.01 |
| 30 Dec 2025 | $0.01 | $0.00 | 0.00% | 219,705 | $0.01 | $0.01 | $0.01 |
| 29 Dec 2025 | $0.01 | $0.00 | 0.00% | 4,014,407 | $0.01 | $0.01 | $0.01 |
| 24 Dec 2025 | $0.01 | $0.00 | 0.00% | 1,160,000 | $0.01 | $0.01 | $0.01 |
| 23 Dec 2025 | $0.01 | $0.00 | 0.00% | 12,431,313 | $0.01 | $0.01 | $0.01 |
| 22 Dec 2025 | $0.01 | $0.00 | 0.00% | 6,166,272 | $0.01 | $0.01 | $0.01 |
| 19 Dec 2025 | $0.01 | $0.00 | 0.00% | 1,870,509 | $0.01 | $0.01 | $0.01 |
| 18 Dec 2025 | $0.01 | $0.00 | 0.00% | 3,182,363 | $0.01 | $0.01 | $0.01 |
| 17 Dec 2025 | $0.01 | $0.00 | 0.00% | 16,081,741 | $0.01 | $0.01 | $0.01 |
| 16 Dec 2025 | $0.01 | $0.00 | 0.00% | 10,356,438 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 06 Jan 2026 | David Stamler | Expiry | 91,392,720 | $822,534 |
Options expired.
|
| 17 Sep 2025 | Lawrence Gozlan | Expiry | 7,000,000 | $77,000 |
Options expired.
|
| 17 Sep 2025 | Geoffrey Kempler | Expiry | 14,000,000 | $154,000 |
Options expired.
|
| 17 Sep 2025 | Brian Meltzer | Expiry | 7,000,000 | $77,000 |
Options expired.
|
| 17 Sep 2025 | Peter Marks | Expiry | 7,000,000 | $77,000 |
Options expired.
|
| 24 Apr 2025 | Brian Meltzer | Issued | 757,576 | $6,060 |
Issue of options.
|
| 24 Apr 2025 | Peter Marks | Issued | 606,061 | $4,848 |
Issue of options.
|
| 24 Apr 2025 | Lawrence Gozlan | Issued | 1,515,152 | $12,121 |
Issue of options.
|
| 07 Apr 2025 | Lawrence Gozlan | Buy | 4,545,455 | $50,000 |
Placement.
|
| 07 Apr 2025 | Peter Marks | Buy | 1,818,182 | $20,000 |
Placement. As per announcement on 09/04/2025.
|
| 07 Apr 2025 | Brian Meltzer | Buy | 2,272,727 | $25,000 |
Placement.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Peter Ashley Marks | Non-Executive Director | Jul 2005 |
Mr Marks has over 35 years of experience in corporate advisory and investment banking. Over the course of his long career, he has specialised in capital raisings, IPOs, cross border, M&A transactions, corporate underwriting and venture capital transactions for companies in Australia, the United States and Israel. He has been involved in a range of transactions with focus in the life sciences, biotechnology, medical technology and segments. He is member of Share Plan Committee.
|
| Mr Lawrence Bernard Gozlan | Non-Executive Director | Aug 2011 |
Mr Gozlan, is a biotechnology investor and advisor, is the Chief Investment Officer and Founder of Scientia Capital, a global investment fund focused exclusively in life sciences. Scientia Capital was founded to provide expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure to the biotechnology industry.
|
| Dr David Stamler | Chief Executive OfficerManaging Director | Jan 2021 |
Dr Stamler was Chief Medical Officer, including advancing the Companys asset toward Phase 3 approval. Dr Stamlers experience, over 30 years in the pharmaceuticals industry, includes guiding three CNS drug approvals with the FDA.
|
| Mr Julian Barbaczy | Non-Executive ChairmanNon-Executive Director | Nov 2025 |
Mr Barbaczy bringing more than 25 years finance and investment industry experience to the Board, having spent almost two-thirds of his career as a member of a Australian funds management group. Julian is currently a Director and/or Chairman of several ASX listed companies.
|
| Ms Abby Macnish Niven | Company Secretary | Nov 2024 |
-
|
| Abby Macnish Niven | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 3,233,367,067 | 35.11% |
| UBS Nominees Pty Ltd | 916,260,279 | 9.95% |
| BNP Paribas Noms Pty Ltd | 386,935,439 | 4.20% |
| J P Morgan Nominees Australia Pty Limited | 351,616,126 | 3.82% |
| Citicorp Nominees Pty Limited | 302,412,580 | 3.28% |
| Kyriaco Barber Pty Ltd | 191,293,455 | 2.08% |
| New Economy Com Au Nominees Pty Limited <900 Account> | 173,648,580 | 1.89% |
| BNP Paribas Noms (Nz) Ltd | 165,346,572 | 1.80% |
| Morgan Stanley Australia Securities (Nominee) Pty Limited <No 1 Account> | 152,699,304 | 1.66% |
| Jagen Nominees Pty Ltd <The B Liberman Family A/C> | 116,492,481 | 1.27% |
| Jing Yang Pty Ltd <Jing Yang Ran Superfund Ac> | 92,748,240 | 1.01% |
| Orchid Bay Investments Pty Ltd <Orchidbay Investments A/C> | 90,909,090 | 0.99% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 86,586,823 | 0.94% |
| Dramista Pty Ltd <Bep Self Managed Sf A/C> | 61,500,000 | 0.67% |
| One Managed Investment Funds Limited <Ti Growth A/C> | 59,038,961 | 0.64% |
| Mrs Amanda Kay Lang | 48,508,594 | 0.50% |
| Buttonwood Nominees Pty Ltd | 46,087,997 | 0.50% |
| Capuano Nominees Pty Ltd <The Hartman Investment A/C> | 45,000,000 | 0.49% |
| Murty Superannuation Pty Ltd <Murty Sf A/C> | 45,000,000 | 0.49% |
| Andrew Mark Wilmot Seton | 44,203,475 | 0.48% |
| BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client> | 43,889,760 | 0.48% |
